ICPT News and Press, Intercept Pharmaceuticals Inc. From 12/08/22

MORRISTOWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, is pleased to share that The American Journal of ...

MORRISTOWN, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President a...

First-in-human data shared at The Liver Meeting ® 2022 supported a favorable safety and tolerability profile for INT-787 in healthy adults Company announces severe alcohol-associated hepatitis (sAH), a disease with no approved therapies, as its lead indication for INT-7...

Intercept Pharmaceuticals ( NASDAQ: ICPT ) announced Monday additional data from its pivotal Phase 3 study for obeticholic acid (OCA) designed to target patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH). A previous readout from the trial named REGENERATE in...

Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral session on Sunday, November 6 MORRISTOWN, N.J., Nov. 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceut...

Summary The 16.4% sales growth of Ocaliva (obeticholic acid or OCA) over the prior year quarter helped lift shares 13.4%. Presentations next week at The Liver Meeting will give a first clinical look at INT-787. More critical is new data from the REGENERATE trial in order to su...

Summary OCALIVA, Intercept's FDA approved therapy, reported nice sales and growth for Q3, 2022; its longer term prospects are clouded. Intercept's lead therapy in development, OCALIVA, is close to resubmitting an sNDA in treatment of NASH; this will be rough sledding. Although...

Intercept Pharmaceuticals, Inc. (ICPT) Q3 2022 Earnings Conference Call November 01, 2022, 08:30 ET Company Participants Nareg Sagherian - Executive Director, Global IR Jerome Durso - President, CEO & Director Linda Richardson - EVP & Chief Commercial Off...

The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Shares of Intercept Pharmaceuticals (NASDAQ: ICPT) were soaring 15.7% higher as of 12:02 p.m. ET on Tuesday. The big gain came after the drugmaker announced its third-quarter results before the market opened. Intercept reported Q3 revenue of $77.6 million, up 16.5% year over yea...